If you were asked to name the hottest topics or trends in the world right now, chances are AI would be one of the first words on your list. And you wouldn’t be alone. In the past five years, AI has become one of the biggest (and most controversial) topics of discussion, dividing the public into two opposite groups.
Whether you love or hate it, it cannot be denied that AI is changing the way we live, work, and interact with each other. According to recent statistics from Forbes:
- 92% of students now use generative AI (such as Copilot or ChatGPT), up from 66% in 2024
- 18% of students who use AI admit to have submitted an AI-generative text in their work
- 78% of organisations use AI, up from 55% in 2024
- 46% of people trust AI
- 76% of experts believe the benefits of AI outweigh the risks
- 40% of jobs are expected to be impacted by AI
The AI industry as a whole is predicted to reach $1 trillion by 2031, with more than 400 million people expected to use AI in some way in 2025. But while most individuals think of AI as their new search engine or personal assistant, many companies have started to utilize AI in smarter and more beneficial ways.
Spectral AI, an AI company focused on medical diagnostics and predictive analytics, is one such company. With their DeepView® Wound Diagnostics System, a revolutionary diagnostic device capable of immediate assessment of a wound’s healing potential, the company is on a mission to provide faster and more accurate treatment insight for burn victims and individuals with diabetic foot ulcers, significantly improving the current standard of care and clinical outcomes.
With a single press of a button, DeepView® creates a scan of the wound, capturing multispectral wound tissue data that cannot be viewed by the naked eye. This data is then transferred to the machine, whose deep learning AI algorithm is capable of critically assessing the wound and determining (with precision) whether it can heal successfully. As a result, in as little as 25 seconds, healthcare professionals are provided with an output that makes patient care easier, faster, and much more efficient.
This proprietary and patented technology is 92% accurate in day 1 burn wound assessments and 86% accurate in DFU wound closure in four weeks. With a total of 26 patents, 12 US and 14 foreign, the company has earned FDA Breakthrough Designation and was granted Best Technology winner for the European Mediscience Awards 2022.
Listed on the Nasdaq Stock Exchange, the company submitted its DeepView® technology to the FDA on June 30, marking an important step towards transforming this promising new technology into an approved solution. Gaining FDA approval will assure institutions that Spectral AI’s DeepView® technology is safe and dependable to use for clinicians, without which any wider adoption of the product is unattainable.
Gaining a green light from the FDA would also help the struggling stock price (ticker: MDAI), as investor confidence is greatly dependent on the FDA clearance. The FDA’s decision is expected to be released in the coming months. As is usually the case with stocks pending FDA approval, should FDA reject DeepView®, we can expect the stock price to plummet hard.
But while even playing in new online casinos might involve less risk than owning the MDAI stock, the potential return can be far greater. The real issue with stocks like MDAI, however, is their volatility. The stock is one bad news away from completely crashing, and once it does, it will be exceedingly difficult for retail investors to resist selling at a loss and instead hold through the crisis.
Penny stocks like MDAI are also more influenced by the wider economic climate–and are usually the first (and hardest) to get hit in case of an economic downturn. But those who invest in companies like Spectral AI know their WHY–they believe in the company and are ready to take on the risk to hopefully reap the benefits in the future. The bottom line? AI can do a lot of good for the world if used responsibly. And Spectral AI is a perfect example of that.
